Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Neurosci.

Sec. Neurodevelopment

Volume 19 - 2025 | doi: 10.3389/fnins.2025.1595880

This article is part of the Research TopicAdvancing Neurodevelopmental Disorder Models with Human iPSC and Multi-Omics IntegrationView all 6 articles

mTORC1-selective inhibitors rescue cellular phenotypes in TSC iPSCderived neurons

Provisionally accepted
Elizabeth  D ButtermoreElizabeth D Buttermore1,2*Gayathri  SrinivasanGayathri Srinivasan1,2Hellen  JumoHellen Jumo2Amanda  C SwansonAmanda C Swanson1,2Benjamin  O'kellyBenjamin O'kelly1,2Nina  R MakhortovaNina R Makhortova1,2Mustafa  SahinMustafa Sahin1,2Stelios  T TzannisStelios T Tzannis3
  • 1Human Neuron Core, Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Boston, United States
  • 2FM Kirby Neurobiology Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, United States
  • 3Aeovian Pharmaceuticals, Inc., Berkeley, California, United States

The final, formatted version of the article will be published soon.

The mechanistic target of rapamycin (mTOR) pathway plays an important role in regulating multiple cellular processes, including cell growth, autophagy, proliferation, protein synthesis, and lipid synthesis, among others. Given the central role of this pathway in multiple cellular processes, it is not surprising that mTOR pathway dysregulation is a key mechanism underlying several neurological disorders, including Tuberous Sclerosis Complex (TSC). TSC patients typically present with pathogenic variants in the TSC1 or TSC2 genes, which encode proteins forming a complex that plays an important role in modulating mTOR activity. We previously reported cellular and functional deficits in induced pluripotent stem cell (iPSC)-derived neurons from TSC patients. These deficits were reversed by inhibiting mTOR activity using rapamycin treatment, revealing the role of mTOR signaling in the regulation of cell morphology and hyperexcitability phenotypes in TSC patient-derived neurons. However, chronic rapamycin treatment inhibits both mTORC1 and mTORC2 activity and its clinical use is associated with significant side effects. With the development of novel mTORC1-selective compounds, we aimed to assess whether selective inhibition of mTORC1 likewise reversed the cellular and functional deficits found in TSC patient-derived neurons. Our results indicate that the novel, selective mTORC1 inhibitors nearly fully reversed the cellular and functional deficits of TSC2-/- iPSC-derived neurons in a fashion and magnitude similar to rapamycin, as they all reversed and near-normalized their neuronal hyperexcitability and abnormal morphology as compared to the DMSO-treated cells. These data suggest that mTORC1-specific compounds could provide clinical therapeutic benefit similar to rapamycin without the same side effects.

Keywords: mTORC1, mTORC2, IPSC-derived neurons, TSC2, mTOR, hyperexcitability, pS6, pAKT

Received: 18 Mar 2025; Accepted: 30 Jun 2025.

Copyright: © 2025 Buttermore, Srinivasan, Jumo, Swanson, O'kelly, Makhortova, Sahin and Tzannis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Elizabeth D Buttermore, Human Neuron Core, Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital, Boston, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.